Recent Updates
Recently added Catalysts
RANI Positive Sentiment Score: 70/100

Rani Therapeutics to Participate in August Investor Conferences

Key Takeaway: Rani Therapeutics Holdings, Inc. will participate in two investor conferences in August 2024, including the BTIG Virtual Biotechnology Conference and the Canaccord 44th Annual Growth Conference. The CEO, Talat Imran, will present at the Canaccord conference. Rani specializes in the oral delivery of biologics and has developed the RaniPill® capsule aimed at replacing traditional injection methods. This engagement may help the company to strengthen investor relations and broaden its market presence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rani Therapeutics is actively engaging with investors through participation in key conferences.
  • The company is showcasing its innovative RaniPill® capsule technology, which could transform drug delivery.
  • Participation in recognized investor conferences may enhance visibility and attract further investment.

Full Press Release Details

SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in August 2024. These conferences include:
BTIG Virtual Biotechnology Conference
Date: Monday, August 5th – Tuesday, August 6th, 2024
Format: 1x1 Investor Meetings
Canaccord 44th Annual Growth Conference
Location: Intercontinental Hotel, Boston, MA
Date: Tuesday, August 13th, 2024 at 3:30pm E.T.
Format: Company Presentation and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran
Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Rani Therapeutics website. The webcast replays will be available after the conclusion of the respective presentations.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Tags

Frequently Asked Questions

What are the dates for Rani Therapeutics' upcoming conferences?

Rani Therapeutics will participate in conferences on August 5-6 and August 13, 2024.

Who will present at the Canaccord conference?

Chief Executive Officer Talat Imran will present at the Canaccord conference.

How can I access the live webcasts of the conferences?

Live webcasts can be accessed via the 'Events' section on the Rani Therapeutics website.

What is the focus of Rani Therapeutics?

Rani Therapeutics focuses on oral delivery of biologics and developing innovative drug technologies.

What is the RaniPill® capsule?

The RaniPill® capsule is a patented technology designed for oral administration of biologics.

Last updated: Jul 29, 2024